Get the latest news, insights, and market updates on TNDM (Tandem Diabetes Care, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Tandem Diabetes Care (TNDM): Assessing Valuation After Record Q3 Sales, Margin Gains, and New Innovation Boosts
Tandem Diabetes Care (TNDM) surged after posting record third-quarter sales and improved gross margins. The company brushed off the impact of a recent voluntary device correction earlier in the year. The latest earnings results beat market expectations and reflected ongoing operational progress. See our latest analysis for Tandem Diabetes Care. Tandem Diabetes Care’s share price bounced sharply, gaining nearly 22% in a single day after record third-quarter revenue and easier gross margin... Nov 9, 2025 - $TNDM
TNDM Q3 Deep Dive: Commercial Transformation and New Product Initiatives Drive Results
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 2.6% year on year to $249.3 million. Its GAAP loss of $0.31 per share was 3.6% above analysts’ consensus estimates. Nov 7, 2025 - $TNDM
Why Is Tandem Diabetes (TNDM) Stock Soaring Today
Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) jumped 20.3% in the afternoon session after the company reported third-quarter results that surpassed analyst expectations for both revenue and earnings per share. Nov 7, 2025 - $TNDM
Why Tandem Diabetes (TNDM) Shares Are Plunging Today
Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) fell 5.1% in the morning session after analyst projections for its third-quarter 2025 earnings pointed to a year-on-year revenue decline. Nov 6, 2025 - $TNDM
Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. Nov 6, 2025 - $TNDM
Tandem Diabetes (NASDAQ:TNDM) Beats Expectations in Strong Q3, Stock Jumps 17.5%
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 2.2% year on year to $249.3 million. Its GAAP loss of $0.31 per share was 3.6% above analysts’ consensus estimates. Nov 6, 2025 - $TNDM
Tandem Diabetes Care Announces Third Quarter 2025 Financial Results
SAN DIEGO, November 06, 2025--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2025 and reaffirmed full year 2025 guidance. Nov 6, 2025 - $TNDM
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple